Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kenneth Kenji Tanabe, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Tanabe and Arthur Sober.
Connection Strength

0.744
  1. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer. 2007 Aug 01; 110(3):614-24.
    View in: PubMed
    Score: 0.093
  2. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol. 2005 Sep 20; 23(27):6739-46.
    View in: PubMed
    Score: 0.082
  3. A case-control study of desmoplastic melanoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7529.
    View in: PubMed
    Score: 0.080
  4. Surgical delay and mortality for primary cutaneous melanoma. J Am Acad Dermatol. 2021 Apr; 84(4):1089-1091.
    View in: PubMed
    Score: 0.057
  5. Lymphedema after sentinel lymph node biopsy for cutaneous melanoma: a report of 5 cases. Arch Dermatol. 2000 Apr; 136(4):511-4.
    View in: PubMed
    Score: 0.056
  6. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999 Apr; 134(4):381-7.
    View in: PubMed
    Score: 0.052
  7. Clinical significance of microscopic melanoma metastases in the nonhottest sentinel lymph nodes. JAMA Surg. 2015 May; 150(5):465-72.
    View in: PubMed
    Score: 0.040
  8. Outcome of patients with de novo versus nevus-associated melanoma. J Am Acad Dermatol. 2015 Jan; 72(1):54-8.
    View in: PubMed
    Score: 0.038
  9. The distribution of microscopic melanoma metastases in sentinel lymph nodes: implications for pathology protocols. Am J Surg Pathol. 2012 Dec; 36(12):1841-8.
    View in: PubMed
    Score: 0.034
  10. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol. 2013 Jan; 44(1):87-94.
    View in: PubMed
    Score: 0.033
  11. The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. Cancer. 2009 Nov 01; 115(21):5071-83.
    View in: PubMed
    Score: 0.027
  12. Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. Cancer. 2009 Nov 01; 115(21):5084-94.
    View in: PubMed
    Score: 0.027
  13. How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. Cancer. 2009 Nov 01; 115(21):5095-107.
    View in: PubMed
    Score: 0.027
  14. Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? Arch Surg. 2004 Apr; 139(4):400-4; discussion 404-5.
    View in: PubMed
    Score: 0.018
  15. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer. 2000 Jul 15; 89(2):356-62.
    View in: PubMed
    Score: 0.014
  16. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45.
    View in: PubMed
    Score: 0.014
  17. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer. 1999 Aug 15; 86(4):617-27.
    View in: PubMed
    Score: 0.013
  18. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13141-6.
    View in: PubMed
    Score: 0.013
  19. Surgical management of primary cutaneous melanomas of the hands and feet. Ann Surg. 1997 May; 225(5):544-50; discussion 550-3.
    View in: PubMed
    Score: 0.011
  20. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther. 1997 Jan 01; 8(1):111-23.
    View in: PubMed
    Score: 0.011
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.